Diets · Metabolic & Cardiometabolic
low LDL cholesterol decreases subclinical atherosclerosis
In plain terms: Does very low LDL mean less plaque in your arteries?
Strong support Diets 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.76
Yes, less — but not none. A large imaging cohort found plaque in a substantial share of people even with LDL under 70, so very low LDL lowers but does not eliminate subclinical atherosclerosis (residual risk).
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
7 support 0 contradict 1 tested null 2 mixed · 10 sources, 6 independent groups
What the evidence shows
Optimal LDL does NOT guarantee absence of plaque: in PESA, subclinical atherosclerosis was present in a large fraction of people with optimal LDL and no risk factors. This supports the honest point (which Norwitz pushes hard) that LDL is necessary-but-not-sufficient - while remaining fully compatible with LDL being causal and worth lowering.
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Georgakis MK, Malik R, Burgess S, Dichgans M 2022 · J Am Heart Assoc | observational | supports | moderate | UKB factorial MR n=408225 additive LDL-lowering benefit confirmed FT |
| Mendieta G, Pocock S, Mass V, Moreno A, Owen R, García-Lunar I, López-Melgar B, Fuster JJ, Andres V, Pérez-Herreras C, Bueno H, Fernández-Ortiz A, Sanchez-Gonzalez J, García-Alvarez A, Ibáñez B, Fuster V 2023 · J Am Coll Cardiol | observational | mixed | moderate | PESA 6y: LDL-C a key determinant of atherosclerosis progression AND regression — low/lowered LDL favors regression (supports LDL-lowering) yet baseline plaque exists at low LDL (residual). Net: compatible. |
| Wang N, Woodward M, Huffman MD, Rodgers A 2022 · Circ Cardiovasc Qual Outcomes | meta-analysis | supports | high | Meta-analysis of 21 randomised trials of statins, ezetimibe and PCSK9 inhibitors in 184,012 patients, average follow-up 4.4 years. The benefit of lowering LDL cholesterol grew the longer treatment continued: each 1 mmol/L reduction cut major vascular events - cardiovascular death, heart attack, stroke or coronary revascularisation - by 12% (95% CI 8-16%) in year 1, 20% (16-24%) by year 3, 23% (18-27%) by year 5 and 29% (14-42%) by year 7. Every endpoint was a clinical event; the paper does not report plaque imaging or any direct measure of atherosclerosis. |
| Grobbee DE, Bots ML 2004 · Cardiology | observational | supports | moderate | Vascular-imaging review: statin LDL lowering slows progression and promotes regression of subclinical atherosclerosis (CIMT/IVUS). |
| Dalakoti M, Chen CK, Sia CH, Poh KK 2025 · Singapore Med J | observational | supports | low | Review: risk-factor levels conventionally considered safe, including LDL-C, may still permit subclinical atherosclerosis - a nuance that low LDL reduces but does not abolish subclinical burden. |
| Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, García-Ruiz JM, Mendiguren J, Bueno H, Pocock S, Ibáñez B, Fernández-Ortiz A, Sanz J 2017 · J Am Coll Cardiol | observational | supports | moderate | Pesa-2017 PESA n=1779 CVRF-free 49.7% plaque LDL OR 1.14-1.18/10mg (DUP of pesa-2017) ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
| Raposeiras-Roubin S, Rosselló X, Oliva B, Fernández-Friera L, Mendiguren JM, Andrés V, Bueno H, Sanz J, Martínez de Vega V, Abu-Assi E, Iñiguez A, Fernández-Ortiz A, Ibáñez B, Fuster V 2021 · J Am Coll Cardiol | observational | tested-null | moderate | PESA: even with LDL-C below guideline thresholds, higher triglycerides linked to more subclinical atherosclerosis/vascular inflammation — residual atherosclerotic risk at low LDL. |
| Di Giacomo Barbagallo F, Bosco G, Di Marco M, Scilletta S, Miano N, Musmeci M, Martedì M, González-Lleó AM, Ibarretxe D, De Francesco EM, Malaguarnera R, Di Pino A, Masana L, Purrello F, Piro S, Scicali R 2025 · Cardiovasc Diabetol | observational | mixed | moderate | FH subjects: subclinical atherosclerosis tracked LDL burden but genotype modified glycemic/atherosclerotic injury; LDL not sole determinant. |
| Mancini GBJ, Hegele RA 2018 · Can J Cardiol | observational | supports | moderate | Perspective/narrative review, no own data: 'On the basis of these convergent and internally consistent lines of evidence, in this article we speculate on a translational paradigm aimed at eliminating LDL-C-related CVEs'. Summarises that 'treatment to this low range is associated with regression and stabilization of established atherosclerosis.' Review — zero weight. |
| Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE 2018 · J Am Coll Cardiol | RCT | supports | high | Evolocumab-driven LDL lowering shifted coronary plaque composition favorably in statin-treated patients (GLAGOV substudy). |
| Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA, Flack JM 2012 · J Am Coll Cardiol | observational | supports | high | [FT-verified] MR meta 9 SNPs ~3x CHD reduction for lifelong-lower LDL |
| Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL 2017 · European Heart Journal | observational | supports | high | EAS consensus integrating genetic/epidemiologic/RCT evidence: LDL causally drives ASCVD; lower lifetime LDL means less atherosclerosis, dose-dependent. |
| Ueki Y, Itagaki T, Kuwahara K 2024 · J Atheroscler Thromb | observational | supports | moderate | Imaging review: LDL lowering with statin+ezetimibe+PCSK9i consistently reduces coronary plaque burden and improves composition. |
| Faridi KF, Lahan S, Budoff MJ, Cury RC, Feldman T, Pan AP, Fialkow J, Nasir K 2024 · JACC Adv | observational | supports | moderate | Miami Heart Study, 1,033 low-risk adults: coronary atherosclerosis prevalence rose stepwise with LDL-C (13.2% at LDL <70 mg/dL, increasing at higher LDL) - lower LDL tracks less subclinical coronary disease. |
| Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE 2016 · JAMA | RCT | supports | high | GLAGOV: adding evolocumab to statins lowered LDL and regressed coronary atheroma volume by IVUS vs statin alone. |
| Oliver W, Giugliano RP 2023 · Curr Atheroscler Rep | RCT | supports | high | IMPROVE-IT: ezetimibe added to statin further lowered LDL and reduced cardiovascular events after ACS ('even lower is even better'). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.